# US 2026/0091059 A1 · Anti-aging compositions and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091059 A1
- Document ID: US20260091059A1
- Status: Published application
- Kind: A1
- Application number: 19/413,965
- Filed: 2025-12-09
- Published: 2026-04-02
- Earliest claimed: 2021-01-06
- Assignees: Yuvan Research, Inc.
- Applicants: Yuvan Research, Inc.
- Inventors: Harold KATCHER; Akshay SANGHAVI
- Web page: https://patentgrep.com/patent/US20260091059A1

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 35/19: Platelets; Megacaryocytes
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 11/08: Bronchodilators
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 39/00: General protective or antinoxious agents
- A61K 2236/39: Complex extraction schemes, e.g. fractionation or repeated extraction steps
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein is a composition comprising a concentrated purified plasma fraction that can be used to treat age-related disorders. Also provided herein are methods for producing a composition comprising a concentrated purified plasma fraction.

## Claims

### Claim 1

A method of preparing a composition comprising a concentrated, purified plasma fraction, wherein the method comprises the following steps in order:
a) isolating a crude plasma fraction from a composition comprising plasma and platelets;
b) incubating a solution comprising the crude plasma fraction of step a) with polyethylene glycol (PEG);
c) centrifuging the plasma fraction and polyethylene glycol solution of step b) to generate a sediment;
d) resuspending the sediment in a buffer and applying the resuspended sediment to a size exclusion chromatography matrix;
e) eluting fractions from the size exclusion chromatography matrix; and
f) concentrating the eluted fractions to provide the concentrated, purified plasma fraction.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprising plasma and platelets is obtained from a mammal.

### Claim 3 (depends on 2)

The method of claim 2, wherein the mammal is a pig, a cow, a goat, a sheep, or a human.

### Claim 4 (depends on 2)

The method of claim 2, wherein the mammal is selected such that its plasma will not cause an immune reaction with an intended recipient.

### Claim 5 (depends on 2, 3, 4)

The method of any one of claims 2-4, wherein the mammal is a healthy juvenile or adolescent mammal.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein isolating the crude plasma fraction from a composition comprising plasma and platelets in step a) comprises centrifugation of the composition comprising plasma and platelets.

### Claim 7 (depends on 6)

The method of claim 6, wherein the composition comprising plasma and platelets is centrifuged at room temperature.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the PEG has an average molecular weight of between 15 kD to 30 kD.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the solution comprising the crude plasma fraction and PEG is incubated 7 hours to 14 hours in step b).

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9, wherein in step c), the crude plasma fraction and polyethylene glycol solution is centrifuged at about 1000×g for at least five minutes at about 4° C.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the size exclusion chromatography matrix is a Sephadex G100 column or a Sephacryl S300.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any one of claims 1-11, wherein the eluted fractions are concentrated in step f) by dialyzing the eluted fractions with a membrane with a molecular weight cut off of from 12 kD to 14 kD.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1-12, further comprising resuspending the concentrated, purified plasma fraction in step f) in saline to produce a pharmaceutical composition.

### Claim 14 (depends on 13)

The method of claim 13, further comprising lyophilizing the pharmaceutical composition.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, further comprising measuring the protein level in the crude plasma fraction produced in step a).

### Claim 16 (depends on 15)

The method of claim 15, wherein the protein concentration in the crude plasma fraction is 6 g/dL to 11 g/dL.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the crude plasma fraction in step a) is not hemolyzed.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the composition comprising plasma and platelets is blood.

### Claim 19 (depends on 18)

The method of claim 18, wherein the blood is obtained by venipuncture of a jugular vein.

### Claim 20 (depends on 19)

The method of claim 19, wherein the blood is collected in a container comprising acid citrate dextrose buffer.

### Claim 21 (depends on 20)

The method of claim 20, wherein the blood is collected aseptically.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A composition comprising the concentrated, purified plasma fraction produced by the method of any one of claims 1-21.

### Claim 23 (depends on 22)

The composition of claim 22, wherein the composition is a pharmaceutical composition.

### Claim 24 (depends on 23)

The composition of claim 23, wherein the pharmaceutical composition is sterile.

### Claim 25

A pharmaceutical composition comprising a concentrated, purified plasma fraction obtained from a mammal, wherein the composition comprises a plasma fraction that is concentrated at least 10 fold compared to the mammal from which the fraction was obtained.

### Claim 26 (depends on 23, 24)

The composition of claim 24 or pharmaceutical composition of claim 23, wherein the composition comprises extracellular vesicles, exosomes, exomeres, nonmembrane bound proteins, exogenous proteins and other molecules and molecular complexes.

### Claim 27 (depends on 22, 23, 24, 25, 26)

The composition of claim 22 or the pharmaceutical composition of any one of claims 23-26, wherein the composition or pharmaceutical composition comprises CD63, CD81, and/or CD9.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

A method of treating an age-related disorder in an individual, comprising administering the composition of claim 22 or the pharmaceutical composition of any one of claims 23-27 to the individual, wherein the composition or pharmaceutical composition is obtained from a young animal of a different species than the individual, wherein the individual and the young animal are both mammals.

### Claim 29 (depends on 28)

The method of claim 28, wherein one or more marker of inflammation or oxidative stress is reduced upon administration of the composition or the pharmaceutical composition.

### Claim 30 (depends on 28, 29)

The method of claim 28 or 29, wherein the age-related disorder is selected from the group consisting of arthrosclerosis, senescence, scarcopenia, type II diabetes, COPD, IBD, arthritis, osteoporosis, Alzheimer's disease, dementia, age-related macular degeneration, ocular neovascularization, diabetic retinopathy, glaucoma, fatty liver disease, chronic kidney disease, and obesity.

### Claim 31 (depends on 28, 29, 30)

The method of any one of claims 28-30, wherein the concentrated, purified plasma fraction is concentrated from an initial volume of plasma from the young animal that is at least equal to the total plasma volume of the individual to whom the concentrated, purified plasma fraction is administered.

### Claim 32 (depends on 28, 29, 30, 31)

The method of any one of claims 28-31, wherein the concentrated, purified plasma composition is administered intravenously, transdermally, nasally, or transmucusoly.

### Claim 33 (depends on 22, 23, 24, 25, 26, 27)

A method of treating ageing in an individual comprising administering the purified, concentrated plasma fraction of any one of claims 22-27 to the individual.
